@IHIEurope Project on Combatting #BacterialResistance in Europe. Collaboration between academia&industry for the research & development of new drugs against AMR
⏰Last chance to register for the Post-graduate course offered by @Ecraid in collaboration with @ESCMID. Enhance your skills with the help of top experts like @MarcBonten!
📝ecraid.eu/news/2024-postgrad…
📅 22-24 October 2024
📍 Belgrade, Serbia
⏳ Registration closes 6 October
📣 Calling researchers in clinical microbiology and infectious diseases! Sharpen your skills and refine your research methodologies with this postgraduate course organised by @Ecraid and @ESCMID.
⏰ Limited spots left - register today!
📢 Read all about it! 🗞️ IHI's June newsletter is now live!➡️ europa.eu/!yKbHDh Find out:
☑️ Everything you wanted to know about call 8
☑️ New #EPI solutions
☑️ Research into whether #SmartHomes can predict onset of #dementia
☑️Events to catch up on
#IHITransformingHealth
ALT 📢 Read all about it! 🗞️ IHI's June newsletter is now live!➡️ https://europa.eu/!yKbHDh
☑️ Everything you wanted to know about call 8
☑️ New #EPI solutions
☑️ Research into whether #SmartHomes can predict onset of #dementia
☑️Events to catch up on
#IHITransformingHealth
Day2 of #UADays24 and ready to start with my lecture on the role of clinical trial networks in solving the global #AMR problem. Will address the evolution of @COMBACTE into @Ecraid @IHIEurope@EU_Commission
Aaaand we are here!!! Finally the Uppsala Antibiotic Days have come, sun shinning & blue skies! Follow #UADays24 to see what we are up to 🤓
or 💥FLASH NEWS💥 join the stream to watch any of the talks today and tomorrow if you didn’t get to register!👇🏻
bit.ly/UAD24stream
💡If you're interested in the #AMR results from the @COMBACTE projects, join us on 31 May for our Impact webinar - Combatting antimicrobial restistance🦠: the legacy of the @COMBACTE projects. More info & register here: europa.eu/!V6mTBY
ALT Save the date - 31 May 2024 - to find how the @COMBACTE projects leveraged #PPP to combat #AntimicrobialResistance, which causes more than 35K deaths/year. Register now: https://europa.eu/!V6mTBY #EUResearch #EUInnovation
🦠 The IMI-supported EMBLAVEO®, which received marketing authorisation from the European Commission last week, is desperately needed, says an infectious disease expert involved in the IMI-supported Phase III REVISIT trial.
👀 Read more: europa.eu/!QdG9tT@COMBACTE